Akoustis Technologies, Inc. (AKTSQ)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Inactive · Last trade price on Jan 2, 2026
Akoustis Technologies Revenue
Akoustis Technologies had revenue of $9.03M in the quarter ending September 30, 2024, with 28.92% growth. This brings the company's revenue in the last twelve months to $29.41M, up 2.98% year-over-year. In the fiscal year ending June 30, 2024, Akoustis Technologies had annual revenue of $27.38M with 0.97% growth.
Revenue (ttm)
29.41M
Revenue Growth
+2.98%
P/S Ratio
0.00
Revenue / Employee
251.36K
Employees
117
Market Cap
155.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 27.38M | 263.00K | 0.97% |
| Jun 30, 2023 | 27.12M | 11.77M | 76.68% |
| Jun 30, 2022 | 15.35M | 8.73M | 131.94% |
| Jun 30, 2021 | 6.62M | 4.83M | 269.72% |
| Jun 30, 2020 | 1.79M | 347.00K | 24.05% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAkoustis Technologies News
- 4 days ago - Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 days ago - U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO - Seeking Alpha
- 7 days ago - Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Business Wire
- 8 days ago - Aktis Oncology prices upsized US IPO at $18 per share - Reuters
- 8 days ago - Aktis Oncology Announces Pricing of its Upsized Initial Public Offering - GlobeNewsWire
- 10 days ago - Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies - Seeking Alpha
- 14 days ago - U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week - Seeking Alpha
- 8 months ago - Akoustis Successfully Completes Sale of Assets to SpaceX - Business Wire